专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007040550A2 TORC POLYNUCLEOTIDES AND POLYPEPTIDES, AND METHODS OF USE 审中-公开
标题翻译： TORC多核苷酸和多肽及其使用方法
公开(公告)号：WO2007040550A2
公开(公告)日：2007-04-12
申请号：PCT/US2005/038207
申请日：2005-10-24
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BITTINGER, Mark , LABOW, Mark, Aron
发明人： BITTINGER, Mark , LABOW, Mark, Aron
IPC分类号： C07K14/435
CPC分类号： C07K14/4705 , A61K38/00 , G01N33/5008 , G01N33/5035 , G01N33/5091 , G01N2333/4706
摘要： The present invention relates to a broad range of methods that utilize a transducer of regulated CREB (TORC)-related polynucleotide, polypeptide, or TORC-specific antibody. In addition the invention relates to TORC-related polynucleotide, polypeptide, or TORC-specific antibody compositions, including variants of TORC wild-type sequences. Exemplary methods include a method of stimulating a TORC related process in a cell as well as a method of inhibiting a TORC-related process in a cell, and a method of inhibiting TORC-related processes in a cell. The invention additionally disclosed therapeutic methods of substantially inhibiting the development of, treating, or ameliorating a disease or pathological condition in a subject related to an abnormal level of a TORC-activated process in a cell that includes administering one or more therapeutically effective doses to the subject of either a substance that modulates accumulation of a TORC polypeptide in a subcellular region of the cell, or of a substance that inhibits expression of a TORC polypeptide in the cell. In an additional aspect a method of identifying an agent that modulates the activity of a TORC-related process in a cell is disclosed. In still a further aspect the invention relates to a method of detecting the presence or quantifying the amount of a TORC polypeptide in a sample. In a further aspect, a method is disclosed of determining whether the amount of a TORC polypeptide in a sample differs from the amount of the TORC polypeptide in a reference. An additional aspect relates to a method of contributing to the diagnosis or prognosis of, or to developing a therapeutic strategy for, a disease or pathology in a first subject, wherein the subcellular localization of a TORC polypeptide in the pathology is known to differ from the subcellular localization of the TORC polypeptide in a nonpathological state.
摘要翻译：本发明涉及利用受调节的CREB（TORC）相关多核苷酸，多肽或TORC特异性抗体的换能器的广泛范围的方法。另外，本发明涉及TORC相关多核苷酸，多肽或TORC特异性抗体组合物，包括TORC野生型序列的变体。示例性方法包括刺激细胞中TORC相关过程的方法以及抑制细胞中TORC相关过程的方法以及抑制细胞中TORC相关过程的方法。本发明另外公开了基本上抑制与细胞中TORC激活过程的异常水平相关的受试者中疾病或病理状态的发展，治疗或改善的治疗方法，所述方法包括对所述受试者施用一种或多种治疗有效剂量受试者是调节TORC多肽在细胞亚细胞区积累的物质或抑制细胞中TORC多肽表达的物质的受试者。在另一方面，公开了鉴定调节细胞中TORC相关过程的活性的试剂的方法。在又一方面，本发明涉及检测样品中TORC多肽的存在或定量的方法。另一方面，公开了确定样品中TORC多肽的量与参考中TORC多肽的量是否不同的方法。另一方面涉及有助于第一受试者的疾病或病理的诊断或预后或制定治疗策略的方法，其中病理学中TORC多肽的亚细胞定位已知不同于 TORC多肽在非病理状态下的亚细胞定位。

2. 发明申请

WO2007040550A3 TORC POLYNUCLEOTIDES AND POLYPEPTIDES, AND METHODS OF USE 审中-公开
标题翻译： TORC多核苷酸和多肽，以及使用方法
公开(公告)号：WO2007040550A3
公开(公告)日：2007-06-28
申请号：PCT/US2005038207
申请日：2005-10-24
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BITTINGER MARK , LABOW MARK ARON
发明人： BITTINGER MARK , LABOW MARK ARON
IPC分类号： C07K14/47 , A61K38/00 , A61K39/395
CPC分类号： C07K14/4705 , A61K38/00 , G01N33/5008 , G01N33/5035 , G01N33/5091 , G01N2333/4706
摘要： The present invention relates to a broad range of methods that utilize a transducer of regulated CREB (TORC)-related polynucleotide, polypeptide, or TORC-specific antibody. In addition the invention relates to TORC-related polynucleotide, polypeptide, or TORC-specific antibody compositions, including variants of TORC wild-type sequences. Exemplary methods include a method of stimulating a TORC related process in a cell as well as a method of inhibiting a TORC-related process in a cell, and a method of inhibiting TORC-related processes in a cell. The invention additionally disclosed therapeutic methods of substantially inhibiting the development of, treating, or ameliorating a disease or pathological condition in a subject related to an abnormal level of a TORC-activated process in a cell that includes administering one or more therapeutically effective doses to the subject of either a substance that modulates accumulation of a TORC polypeptide in a subcellular region of the cell, or of a substance that inhibits expression of a TORC polypeptide in the cell. In an additional aspect a method of identifying an agent that modulates the activity of a TORC-related process in a cell is disclosed. In still a further aspect the invention relates to a method of detecting the presence or quantifying the amount of a TORC polypeptide in a sample. In a further aspect, a method is disclosed of determining whether the amount of a TORC polypeptide in a sample differs from the amount of the TORC polypeptide in a reference. An additional aspect relates to a method of contributing to the diagnosis or prognosis of, or to developing a therapeutic strategy for, a disease or pathology in a first subject, wherein the subcellular localization of a TORC polypeptide in the pathology is known to differ from the subcellular localization of the TORC polypeptide in a nonpathological state.
摘要翻译：本发明涉及利用受调节的CREB（TORC）相关多核苷酸，多肽或TORC特异性抗体的转导子的广泛范围的方法。此外，本发明涉及TORC相关多核苷酸，多肽或TORC特异性抗体组合物，包括TORC野生型序列的变体。示例性方法包括刺激细胞中TORC相关过程的方法以及抑制细胞中TORC相关过程的方法，以及抑制细胞中TORC相关过程的方法。本发明另外公开了治疗方法，其基本上抑制与细胞中TORC活化过程的异常水平相关的受试者的疾病或病理状态的发展，治疗或改善，其包括向所述细胞施用一种或多种治疗有效剂量调节细胞亚细胞区域中TORC多肽的积累的物质或抑制细胞中TORC多肽表达的物质的受试者。在另一方面，公开了一种识别调节细胞中TORC相关过程的活性的试剂的方法。在另一方面，本发明涉及检测样品中TORC多肽的存在或定量的方法。在另一方面，公开了确定样品中TORC多肽的量是否与参考文献中TORC多肽的量不同的方法。另一方面涉及有助于诊断或预后的方法，或用于制定第一受试者的疾病或病理学的治疗策略，其中TORC多肽在病理学中的亚细胞定位已知不同于 TORC多肽在非病理状态下的亚细胞定位。

3. 发明申请

WO2007041513A3 CONSERVED MEMBRANE ACTIVATOR OF CALCINEURIN (CMAC), A NOVEL THERAPEUTIC PROTEIN AND TARGET 审中-公开
公开(公告)号：WO2007041513A3
公开(公告)日：2007-04-12
申请号：PCT/US2006/038482
申请日：2006-10-02
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , BITTINGER, Mark , CHOW, Christine , GUERINI, Danilo , LABOW, Mark Aron , LATARIO, Brian Jude , XIONG, Zhao-Hui
发明人： BITTINGER, Mark , CHOW, Christine , GUERINI, Danilo , LABOW, Mark Aron , LATARIO, Brian Jude , XIONG, Zhao-Hui
IPC分类号： C07K14/47 , C07K14/705 , C07K16/28 , C12N15/12 , C12N5/10 , A61P37/00 , A61K38/16 , A61P35/00 , A61P9/00 , A61P25/00
摘要： The invention discloses the first known function and biological activity of the hypothetical protein MGC14327, now designated cMAC, which is herein identified as an important controller of T-cell activation. It is contemplated herein that cMAC is a suitable drug target for the development of new therapeutics to treat cMAC-associated disorders. The invention relates to methods to treat said pathological conditions and to pharmaceutical compositions therefore. The pharmaceutical compositions comprise modulators with inhibitory or agonist effect on cMAC protein activity and/or cMAC gene expression. The invention also relates to methods to identify compounds with therapeutic usefulness to treat said pathological conditions, comprising identifying compounds that can inhibit or agonize cMAC protein activity and/or cMAC gene expression.

4. 发明申请

WO2007041513A2 CONSERVED MEMBRANE ACTIVATOR OF CALCINEURIN (CMAC), A NOVEL THERAPEUTIC PROTEIN AND TARGET 审中-公开
标题翻译： CALCINEURIN（CMAC）的保护膜激活剂，新型治疗蛋白质和目标
公开(公告)号：WO2007041513A2
公开(公告)日：2007-04-12
申请号：PCT/US2006038482
申请日：2006-10-02
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BITTINGER MARK , CHOW CHRISTINE , GUERINI DANILO , LABOW MARK ARON , LATARIO BRIAN JUDE , XIONG ZHAO-HUI
发明人： BITTINGER MARK , CHOW CHRISTINE , GUERINI DANILO , LABOW MARK ARON , LATARIO BRIAN JUDE , XIONG ZHAO-HUI
IPC分类号： C07K14/73
CPC分类号： C07K14/47 , C12N15/1138 , C12N2310/14 , C12N2310/53
摘要： The invention discloses the first known function and biological activity of the hypothetical protein MGC14327, now designated cMAC, which is herein identified as an important controller of T-cell activation. It is contemplated herein that cMAC is a suitable drug target for the development of new therapeutics to treat cMAC-associated disorders. The invention relates to methods to treat said pathological conditions and to pharmaceutical compositions therefore. The pharmaceutical compositions comprise modulators with inhibitory or agonist effect on cMAC protein activity and/or cMAC gene expression. The invention also relates to methods to identify compounds with therapeutic usefulness to treat said pathological conditions, comprising identifying compounds that can inhibit or agonize cMAC protein activity and/or cMAC gene expression.
摘要翻译：本发明公开了现在称为cMAC的假想蛋白质MGC14327的第一已知功能和生物活性，其被鉴定为T细胞活化的重要控制剂。本文预期cMAC是用于开发用于治疗cMAC相关疾病的新治疗剂的合适的药物靶标。本发明涉及治疗所述病理状态的方法和药物组合物。药物组合物包含对cMAC蛋白活性和/或cMAC基因表达具有抑制或激动作用的调节剂。本发明还涉及鉴定具有治疗所述病理状况的治疗有用性的化合物的方法，其包括鉴定可抑制或激动cMAC蛋白活性和/或cMAC基因表达的化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式